reports
Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Tri...
Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Belgium STAFFORD, Texas, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the expansion of FLAMINGO-01 clinical trial to Belgium. The Company's application to European regulators has been formally approved, adding Belgium as an approved country in FLAMINGO-01 in addition to...
Greenwich LifeSciences Announces Addition of Portugal to Flamingo-01 C...
Greenwich LifeSciences Announces Addition of Portugal to Flamingo-01 Clinical Trial STAFFORD, Texas, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the expansion of FLAMINGO-01 clinical trial to Portugal. The Company's application to European regulators has been formally approved, adding Portugal as an approved country in FLAMINGO-01 in addition...
Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Tri...
Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Ireland STAFFORD, Texas, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the expansion of FLAMINGO-01 clinical trial to Ireland. The Company's application to European regulators has been formally approved, adding Ireland as an approved country in FLAMINGO-01 in addition t...
Greenwich LifeSciences’ GLSI-100 Granted US FDA Fast Track Designation
Greenwich LifeSciences’ GLSI-100 Granted US FDA Fast Track Designation STAFFORD, Texas, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that FDA has granted Fast Track designation for GLSI-100 in the HLA-A*02 patient population. The designation specifically states that "GLSI-100 for the treatment of patients with HLA-A*02 genotype and HER2-positi...
Erasca to Present at the Morgan Stanley 23rd Annual Global Healthcare ...
Erasca to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference SAN DIEGO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Morgan Stanley 23rd Annual Global Healthcare Conference being held at the Sheraton New York Times Square in New York, NY. Management will present on Tuesday, September 9, 2025, at 3:20 pm Eastern Time and will also participate...
Noble Capital Markets Initiates Equity Research Coverage on Greenwich ...
Noble Capital Markets Initiates Equity Research Coverage on Greenwich LifeSciences STAFFORD, Texas, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that Noble Capital Markets has initiated company-sponsored equity research coverage on the Company. The full report by Noble Capital Markets Research Analyst Robert LeBoyer is available : About FLAMING...
Greenwich LifeSciences Announces Plan to Build Out Internal Clinical O...
Greenwich LifeSciences Announces Plan to Build Out Internal Clinical Operations Team STAFFORD, Texas, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced its plan to build out its internal clinical trial management and operations team. The Company has begun to hire its own staff to manage and operate FLAMINGO-01, while reducing its dependence on more ...
- Dave Nicoski
- Ross LaDuke
Vermilion Short Shots: Technically Vulnerable Stocks
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
PCTY PAYLOCITY HOLDING CORP.
LNTH LANTHEUS HOLDINGS INC
HUBS HUBSPOT INC.
HAE HAEMONETICS CORPORATION
CRM SALESFORCE.COM INC.
CRK COMSTOCK RESOURCES INC.
CPRX CATALYST PHARMACEUTICALS
AR ANTERO RESOURCES CORPORATION
HRB H&R BLOCK INC.
SNAP SNAP INC. CLASS A
CNX CNX RESOURCES CORPORATION
ACI-R-A ADRIATIC CROATIA INTERNATIONAL CLUB D.D.
HPK HIGHPEAK ENERGY INC (A)
ACVA ACV AUCTIONS INC
CHK CHESAPEAKE ENERGY CORP
BRZE BRAZE INC
SG SWEETGREEN INC
MNDY MONDAY COM LTD
IOT SAMSARA INC
KLC KINDERCARE LEARNING COS INC
TEAM ATLASSIAN CORPORATION
SLDE SLIDE INS HLDG INC
Greenwich LifeSciences Announces Expansion of Flamingo-01 into Romania
Greenwich LifeSciences Announces Expansion of Flamingo-01 into Romania STAFFORD, Texas, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the addition of clinical sites in Romania. The Company's application to expand Flamingo-01 into Romania has been formally approved by European regulators, thus adding Romanian sites to the approximately 150 approv...
Erasca Reports Second Quarter 2025 Business Updates and Financial Resu...
Erasca Reports Second Quarter 2025 Business Updates and Financial Results Efficient execution accelerated clinical entry of pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 Phase 1 monotherapy data for RAS-targeting franchise expected in 2026 Robust balance sheet with cash, cash equivalents, and marketable securities of $387 million as of June 30, 2025 is expected to fund operations into H2 2028 SAN DIEGO, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commerc...
Greenwich LifeSciences Provides Update on CEO Interviews & Corporate E...
Greenwich LifeSciences Provides Update on CEO Interviews & Corporate Events STAFFORD, Texas, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today provided the following update on CEO interviews and corporate events. The following videos, which include CEO interviews, are now available on the Company’s website at the bottom of the Welcome page: Jun 28, 20...
Erasca Announces IND Clearance for Potential First-in-Class and Best-i...
Erasca Announces IND Clearance for Potential First-in-Class and Best-in-Class Pan-KRAS Inhibitor ERAS-4001 Both ERAS-4001 and potential best-in-class pan-RAS molecular glue ERAS-0015 received IND clearance in May ahead of company guidance Initial Phase 1 monotherapy data for both RAS-targeting programs expected in 2026 SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced clearance ...
Erasca to Present at Upcoming Investor Conferences in June
Erasca to Present at Upcoming Investor Conferences in June SAN DIEGO, May 29, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that management will participate in the following investor conferences in June 2025 and will also participate in one-on-one investor meetings at each of these conferences. Jefferies Global Healthcare Conference (June 3-5, 2025)Location: New York, NYFormat: Fireside ChatDate...
Erasca Reports First Quarter 2025 Business Updates and Financial Resul...
Erasca Reports First Quarter 2025 Business Updates and Financial Results Early entry of RAS-targeting franchise into clinic enabled by strong execution Initial Phase 1 monotherapy data for pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 expected in 2026 Robust balance sheet with cash, cash equivalents, and marketable securities of $411 million as of March 31, 2025 with cash runway guidance extended to H2 2028 SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developin...
Erasca Announces Early Clinical Advancement and Prioritization of RAS-...
Erasca Announces Early Clinical Advancement and Prioritization of RAS-Targeting Franchise Coupled with More than 3 Years of Projected Cash Runway IND cleared for pan-RAS molecular glue ERAS-0015 and IND submitted for pan-KRAS inhibitor ERAS-4001, both ahead of schedule; Phase 1 monotherapy data for both programs expected in 2026 Meaningful extension of cash runway guidance from H2 2027 to H2 2028 following strategic decision to pursue partnership opportunities for naporafenib SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology co...
Erasca to Present at the Bank of America Securities Health Care Confer...
Erasca to Present at the Bank of America Securities Health Care Conference SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Bank of America Securities 2025 Health Care Conference being held at the Encore Hotel in Las Vegas, Nevada. Management will present on Wednesday, May 14, 2025, at 2:35 pm Pacific Time and will also participate in one-on-one investor m...
- Jonathan Moreland
PMT PENNYMAC MORTGAGE INVESTMENT TRUST
XPL SOLITARIO ZINC
RGP RESOURCES CONNECTION INC.
OPK OPKO HEALTH INC.
MTDR MATADOR RESOURCES COMPANY
CVGW CALAVO GROWERS INC.
CRMD CORMEDIX INC.
ASPS ALTISOURCE PORTFOLIO SOLUTIONS S.A.
LPG DORIAN LPG
WHF WHITEFIELD
AMTX AEMETIS
GCBC GREENE COUNTY BANCORP INC.
JFR NUVEEN FLOATING RATE INCOME FUND
IIFw MORGAN STANLEY INDIA INVESTMENT FUND INC.
NHF NEXPOINT CREDIT STRATEGIES FUN
DOMO DOMO INCORPORATED
BCDA BIOCARDIA
PCB PACIFIC CITY FINANCIAL CORP
ASAN ASANA
PCVX VAXCYTE
WOOF PETCO HEALTH AND WELLNESS
NUVB NUVATION BIO INC (A)
CTGO CONTANGO ORE INC.
SMMT SUMMIT THERAPEUTICS INC
HUMA HUMACYTE INC
TCBX THIRD COAST BANCSHARES INC
PEPG PEPGEN INC
GLSI GREENWICH LIFESCIENCES INC
JMSB JOHN MARSHALL BANCORP INC
MEGI MAINSTAY CBRE GBL INFRASTRUCTURE MEGATRENDS FD
NMTC NEUROONE MEDICAL TECHNOLOGIES CORP
SSII SS INNOVATIONS INTERNATIONAL INC
CATX PERSPECTIVE THERAPEUTICS
DMA INC.
SUNS DESTRA MULTI ALTERNATIVE FUND
NUTX SUNRISE REALTY TRUST
AFCG NUTEX HEALTH INC
FTLF AFC GAMMA
INC.
FITLIFE BRANDS INC.
- Jonathan Moreland
TTSH TILE SHOP HOLDINGS INC.
TCBI TEXAS CAPITAL BANCSHARES INC.
CDXS CODEXIS
CBRL CRACKER BARREL OLD COUNTRY STORE INC.
BMY BRISTOL-MYERS SQUIBB COMPANY
BANC BANC OF CALIFORNIA INCORPORATED
MRTN MARTEN TRANSPORT LTD.
AVTR AVANTOR
TCBX INC.
GLSI THIRD COAST BANCSHARES INC
JMSB GREENWICH LIFESCIENCES INC
NBBK JOHN MARSHALL BANCORP INC
BHRB NB BANCORP INC.
DMA BURKE HERBERT FINANCIAL SERVICES CORP
DESTRA MULTI ALTERNATIVE FUND
Erasca Presents New Preclinical Data Reinforcing Best-in-Class Potenti...
Erasca Presents New Preclinical Data Reinforcing Best-in-Class Potential of RAS-Targeting Franchise at the 2025 AACR Annual Meeting ERAS-0015 and ERAS-4001 showed robust anti-tumor activity as monotherapy and combination therapy First-in-class examples of direct SHOC2 binders and modulators of SMP complex assembly identified with potential to block oncogenic RAS/MAPK pathway signaling SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patie...
- Jonathan Moreland
LIND LINDBLAD EXPEDITIONS HOLDINGS
IIFw MORGAN STANLEY INDIA INVESTMENT FUND INC.
FEIM FREQUENCY ELECTRONICS INC.
MAV PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
ENX EATON VANCE NEW YORK MUNICIPAL BOND FUND
TEAF ECOFIN SUSTAINABLE AND SOCIAL IMPACT TERM FUND
GLSI GREENWICH LIFESCIENCES INC
MIO PIONEER MUN HIGH INCOME OPPORTUNITIES FD INC
EVM EATON VANCE INSD CALIF MUN BD FD
SCND SCIENTIFIC INDUSTRIES INC
ECF ELLSWORTH FUND LTD
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.